Dr.Neiwete lomi

Dr.ALISHA KISHORE, Dr. (Mrs.) RADHIKA TANDON

Abstract

Objective: To study the early outcomes of episcleral plaque brachytherapy for recalcitrant retinoblastoma.

Methods: Ruthenium-106 episcleral plaque brachytherapy were used to treat 10 eyes in 10 children with recalcitrant retinoblastoma following failure to standard multimodality treatment. All 10 children other eye was enucleated due to advanced stage.

Results: The group comprised of 5 boys and 5 girls. The median age was 55 months (range: 12-180 months). The vision in (LogMAR) (mean±SD) pre application and post application at 12 months was 1.25±0.60 and 1.14±0.74, IOP(mmHg) 11.2±0.97 and 10.7±1.18, tumor apical thickness (mm) 3.65±0.99 and 2.86±2.05, largest basal diameter (mm) 10.15±3.02 and 6.36±3.01. The eye preservation rate in our series was 80% (8/10) at median 12 months follow up.

Conclusion: Plaque brachytherapy is a useful adjuvant treatment for localised tumor that fail to respond to conventional treatment.

Keywords: Retinoblastoma, Ruthenium 106, Brachytherapy

Full Text